Evidence map›Paper›PMID 39883056›Full record

ArticleNeuro-oncology2025

Tumor cells upregulate neurotransmitter GABA in the choroid plexus through STAT6-Bestrophin1 signaling, promoting leptomeningeal dissemination.

Diganta Das, Mukund Iyer, Brooke Nakamura, Saman Sedighi, Angela Hsu, Camelia Danilov, Peter S LaViolette, Jennifer Connelly, Frances Chow, Josh Neman

Abstract read
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Diganta DasNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Mukund IyerNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Brooke NakamuraNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Saman SedighiNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Angela HsuLife Science Department, University of Bristol, Bristol, UK.
Camelia DanilovDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Peter S LaVioletteDepartment of Radiology, Biophysics, and Biomedical Engineering, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Jennifer ConnellyDepartment of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Frances ChowNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Josh NemanNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-6337-9615

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Mentored Career DevelopmentKL2TR001854 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Elizabeth Rhea Erwin Burner, Amy Elizabeth West · 2016 to 2026
$9.0M
Prostate Cancer Radio-Pathomics for Differentiating Clinically Significant DiseaseR01CA249882 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI LAVIOLETTE, PETER S · 2021 to 2025
$3.0M
Microenvironmental contribution of the Choroid Plexus and Cerebral Spinal Fluid in breast to brain metastasesR01CA223544 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI NEMAN-EBRAHIM, JOSH · 2019 to 2023
$2.3M
The Role of GABA Transaminase ABAT in Pediatric Brain Tumor Medulloblastoma Development and SpreadR01NS133038 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANAT ERDREICH-EPSTEIN, Josh Neman-Ebrahim · 2023 to 2026
$2.2M
Brain Cancer Radio-Pathomics for Predicting Heterogeneous CytologyR01CA218144 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI LAVIOLETTE, PETER S · 2017 to 2021
$1.9M
Small Animal Photoacoustic Imaging Unit: Integrating Optical Imaging with High FrS10OD018096 · OD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CONTI, PETER STEPHEN · 2014 to 2014
$599k
IVIS Spectrum Optical Imaging Core ResourceS10OD021785 · OD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CONTI, PETER STEPHEN · 2017 to 2017
$408k
American Cancer Society IRG-22-144-60NCATS NIH HHS KL2 TR001854NCATS NIH HHS KL2TR001854NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA218144NCI NIH HHS R01 CA223544NCI NIH HHS R01 CA249882NIH HHS 1R01NS133038NIH HHS P30CA014089NIH HHS R01CA218144NIH HHS R01CA223544-01A1NIH HHS R01CA249882NIH HHS S10 OD018096NIH HHS S10OD018096NIH HHS S10 OD021785NIH HHS S10OD021785NINDS NIH HHS R01 NS133038
6 · The paper itself

Abstract

backgroundLeptomeningeal dissemination (LMD) occurs when tumor cells interact with choroid plexus epithelium (CPE) to gain access to cerebrospinal fluid (CSF) in the brain's meninges and ventricular system. This disease is particularly devastating for patients due to our limited understanding and few therapeutic options. The leptomeningeal CSF is a nutritionally deprived microenvironment for tumor cells. Despite this, LMD tumor cells survive by taking up and metabolizing the neurotransmitter gamma-aminobutyric acid (GABA) from the CSF. However, we currently lack evidence on how CSF-GABA levels are altered and how tumor cells communicate with the CPE to increase GABA levels in the LMD microenvironment. Herein, we examined the interactions between CPEs and tumor cells that make CSF more hospitable to LMD growth.

methodsPrimary choroid plexus, breast cancer cells, and patient-derived breast and lung-to-brain metastatic cells, are utilized in in vivo metastatic /LMD modeling along with signal transducer and activator of transcription 6 (STAT6) inhibitor and IL13 gene knockdown.

resultsWe show breast and lung cancer cells derived-IL13 activates STAT6 signaling in choroid plexus. Subsequently, choroid plexus upregulates GABA-synthesizing enzyme GAD67 and GABA-permeable channel Bestrophin1, all leading to elevated neurotransmitter GABA levels in the CSF. Moreover, we show a significant reduction of Bestrophin1 in choroid plexus when tumor-derived IL13 is knocked down or when treated with brain permeable STAT6 specific inhibitor AS1517499, leading to increased survival.

conclusionsOverall, these findings reveal a novel STAT6-Bestrophin1-GABA axis in choroid plexus and its therapeutic targeting can lead to favorable outcomes in leptomeningeal disease.

Indexed as

BestrophinsChoroid Plexusgamma-Aminobutyric AcidMeningeal NeoplasmsSTAT6 Transcription FactorAnimalsFemaleHumansMiceSignal TransductionTumor Cells, CulturedUp-RegulationBEST1 protein, humanBestrophinsgamma-Aminobutyric AcidSTAT6 protein, humanSTAT6 Transcription FactorBestrophin1choroid plexusGABAleptomeningeal metastasisSTAT6

Identifiers

PMID39883056
PMCPMC12309716

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.